INTRODUCTION {#s1}
============

Cancer is a substantial public health burden, with an estimated 1.7 million new cancer cases and 0.6 million cancer-related deaths in the United States in 2016 \[[@R1]\]. Although the etiology of carcinogenesis has not yet been fully elucidated, many lines of evidence suggest that cancer is a multifactorial disease caused by intricate interactions between multiple hereditary and environmental factors \[[@R2], [@R3]\]. Numerous studies have demonstrated that inflammation is critically implicated in the development of some cancers \[[@R4], [@R5]\]. In view of this, it is plausible that genetic polymorphisms in inflammation-related genes could modify cancer susceptibility \[[@R6]--[@R8]\].

Nuclear factor-kappa B (NF-κB) is a pleiotropic transcription factor discovered by Sen and Baltimore in 1986 \[[@R9]\]. In mammals, the NF-κB family consists of five members: c-Rel (Rel), Rel B, p65 (RelA), p50/p105 (NF-κB1), and p52/p100 (NF-κB2) \[[@R10]\]. This group of molecules function as key regulators of a variety of genes implicated in diverse biological events including cell survival, apoptosis, inflammation, differentiation, and autophagy \[[@R11], [@R12]\]. Recently, high levels of NF-κB have been observed in many cancers, including pancreatic cancer \[[@R13]\], lung cancer \[[@R14]\], colorectal cancer \[[@R15]\], breast cancer \[[@R16]\], melanoma \[[@R17]\], and multiple myeloma \[[@R18]\]. Although various dimeric forms of NF-κB exist, the most common is the p50 and p65/RelA heterodimer, encoded by the *NFKB1* and *RelA* genes, respectively \[[@R19]\].

The human *NFKB1* gene, spanning 156-kb, is located on chromosome 4q23-q24 and encodes a 105 kD protein (p105) which is cleaved into an active subunit (p50) \[[@R20]\]. Several variations have been identified in the *NFKB1* gene, including rs72696119 (C\>G), rs28362491 (-94 ins/del ATTG), rs4648068 (A\>G), and rs12509517 (G\>C) \[[@R21]\]. Among these, *NFKB1* rs28362491, namely the -94insertion/deletion ATTG polymorphism, is potentially functional and the most widely investigated \[[@R21]\]. This modification occurs between two important regulatory elements (activator protein 1 and κB binding site) in the promoter region of the *NFKB1* gene. The deletion of four bases (ATTG) reduces or prevents the binding to nuclear proteins and leads to lower transcript levels of the *NFKB1* gene, thereby changing mRNA stability and regulating translation efficiency \[[@R21], [@R22]\].

Numerous case-control studies have assessed the association between the *NFKB1* -94ins/delATTG promoter polymorphism and cancer risk, with discrepant results. While some studies indicated an increased risk for some types of cancers \[[@R23]--[@R25]\], other studies showed instead a decreased risk, or no association \[[@R26], [@R27]\]. Several meta-analyses attempted to solve the controversy, but did not yield consistent results \[[@R28]--[@R33]\]. To provide a more precise evaluation of such association, we performed a comprehensive, updated meta-analysis. In addition, to minimize random errors and strengthen the robustness of our conclusions, we also performed trial sequential analysis (TSA).

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The study selection process for this meta-analysis is shown in Figure [1](#F1){ref-type="fig"}, 258 potentially relevant published records were retrieved from PubMed, EMBASE, China National Knowledge infrastructure (CNKI), and WANFANG databases. After screening the titles and reading the abstracts, 69 studies remained and were carefully reviewed. Among these, 23 publications were further excluded: 7 were case-only studies \[[@R34]--[@R39]\]; 6 were meta-analyses \[[@R28]--[@R33]\]; 5 deviated from Hardy-Weinberg equilibrium (HWE) \[[@R40]--[@R44]\]; 3 were duplicated publications \[[@R45]--[@R47]\]; 1 was a review \[[@R48]\], and 1 lacked sufficient data to calculate odds ratio (OR) and 95% confidence interval (CI) \[[@R49]\]. Thus, 46 publications were included in the final analysis \[[@R23]--[@R27], [@R48], [@R50]--[@R89]\]. Among these, publications that contained different case groups but used the same controls, or that studied one cancer type in different populations, were considered separate studies.

![Flowchart of the study inclusion protocol](oncotarget-08-9806-g001){#F1}

After this selection procedure, 50 studies extracted from 46 publications with 18,299 cases and 23,484 controls ultimately entered our final meta-analysis (Table [1](#T1){ref-type="table"}). 38 of these studies included Asians subjects, and 12 included Caucasians. Regarding cancer types, 6 studies addressed hepatocellular carcinoma, 5 lung cancer, 4 colorectal cancer, 4 nasopharyngeal carcinoma, 4 prostate cancer, 4 ovarian cancer, 3 bladder cancer, 3 gastric cancer, 3 cervical cancer, 2 oral squamous cell carcinoma, 2 breast cancer, and 10 studies addressed other cancers. Moreover, 40 studies used a population-based design, and 10 were hospital-based. 19 studies had a quality score \>9, and the remaining 31 had a quality score ≤9.

###### Characteristics of the studies included in the current meta-analysis

  Surname                Year   Cancer type         Country   Ethnicity   Control Source   Genotype method   Case   Control   MAF   HWE    Score                                     
  ---------------------- ------ ------------------- --------- ----------- ---------------- ----------------- ------ --------- ----- ------ ------- ----- ----- ------ ------ ------- ----
  Lin \[[@R25]\]         2006   OSCC                China     Asian       HB               PCR-PAGE          59     103       50    212    43      100   58    201    0.54   0.993   7
  Riemann \[[@R26]\]     2006   Colorectal cancer   Germany   Caucasian   HB               Pyro sequencing   54     58        27    139    118     141   48    307    0.39   0.586   9
  Riemann \[[@R26]\]     2006   CLL                 Germany   Caucasian   HB               Pyro sequencing   18     41        13    72     118     141   48    307    0.39   0.586   9
  Riemann \[[@R26]\]     2006   RCC                 Germany   Caucasian   HB               Pyro sequencing   47     76        17    140    118     141   48    307    0.39   0.586   9
  Bu \[[@R48]\]          2007   Melanoma            Sweden    Caucasian   HB               PCR-RFLP          67     84        34    185    116     255   67    438    0.44   0.000   10
  Riemann \[[@R83]\]     2007   Bladder cancer      Germany   Caucasian   HB               Pyro sequencing   88     124       30    242    118     141   48    307    0.39   0.586   10
  Lehnerdt \[[@R27]\]    2008   HNSCC               Germany   Caucasian   HB               Pyro sequencing   132    179       53    364    118     141   48    307    0.39   0.586   8
  He \[[@R82]\]          2009   HCC                 China     Asian       HB               PCR-RFLP          83     84        35    202    97      183   124   404    0.53   0.070   9
  He \[[@R89]\]          2009   HCC                 China     Asian       HB               PCR-RFLP          55     65        30    150    70      136   94    300    0.54   0.130   8
  Lo \[[@R24]\]          2009   Gastric cancer      China     Asian       HB               PCR               62     89        31    182    20      62    34    116    0.56   0.361   7
  Zhang \[[@R81]\]       2009   Prostate cancer     China     Asian       HB               PCR-PAGE          46     57        14    117    44      68    31    143    0.45   0.624   8
  Zhou \[[@R80]\]        2009   NPC                 China     Asian       HB               PCR-PAGE          74     67        22    163    71      90    42    203    0.43   0.177   7
  Tang \[[@R79]\]        2010   Bladder cancer      China     Asian       HB               PCR--PAGE         89     92        26    207    74      108   46    228    0.44   0.565   10
  Zhou \[[@R78]\]        2010   Cervical cancer     China     Asian       HB               PCR--PAGE         108    105       20    233    135     166   64    365    0.40   0.297   9
  Fan \[[@R77]\]         2011   Ovarian cancer      China     Asian       HB               PCR-CE            78     84        17    179    76      103   44    223    0.43   0.396   8
  Lin \[[@R76]\]         2012   OSCC                China     Asian       HB               TaqMan            116    246       100   462    81      271   168   520    0.58   0.099   9
  Song \[[@R92]\]        2012   Colorectal cancer   China     Asian       HB               PCR-RFLP          363    500       138   1001   297     522   186   1005   0.44   0.102   14
  Tang \[[@R87]\]        2012   HCC                 China     Asian       HB               PCR-RFLP          52     84        14    150    57      82    11    150    0.35   0.011   7
  Ungerback \[[@R75]\]   2012   Colorectal cancer   Sweden    Caucasian   HB               TaqMan            114    187       43    344    256     270   96    622    0.37   0.079   8
  Vangsted \[[@R74]\]    2012   Multiple myeloma    Denmark   Caucasian   PB               TaqMan            110    163       55    328    655     778   253   1686   0.38   0.303   7
  Arisawa \[[@R73]\]     2013   Gastric cancer      Japan     Asian       PB               PCR-SSCP          172    239       68    479    342     435   103   880    0.36   0.046   11
  Cheng \[[@R23]\]       2013   HCC                 China     Asian       HB               TaqMan            42     64        29    135    81      271   168   520    0.58   0.099   7
  Huang \[[@R72]\]       2013   Lung cancer         China     Asian       PB               TaqMan            372    459       225   1056   355     491   210   1056   0.43   0.090   10
  Huang \[[@R72]\]       2013   Lung cancer         China     Asian       PB               TaqMan            169    230       104   503    189     289   145   623    0.46   0.092   10
  Huo \[[@R71]\]         2013   Ovarian cancer      China     Asian       HB               Mass ARRAY        83     82        22    187    71      103   47    221    0.45   0.399   7
  Kopp \[[@R70]\]        2013   Prostate cancer     Denmark   Caucasian   PB               RT-PCR            128    152       54    334    109     161   64    334    0.43   0.741   11
  Li \[[@R69]\]          2013   Bladder cancer      China     Asian       HB               TaqMan            189    269       151   609    223     324   93    640    0.40   0.156   11
  Liu \[[@R86]\]         2013   NPC                 China     Asian       PB               TaqMan            116    135       49    300    86      143   71    300    0.48   0.443   12
  Song \[[@R84]\]        2013   EC                  China     Asian       HB               PCR-RFLP          42     52        6     100    56      39    5     100    0.25   0.588   6
  Song \[[@R85]\]        2013   Cervical cancer     China     Asian       HB               PCR-RFLP          34     56        10    100    37      55    8     100    0.36   0.044   5
  Umar \[[@R68]\]        2013   ESCC                India     Asian       HB               PCR               131    132       27    290    160     129   22    311    0.28   0.561   10
  Gao \[[@R67]\]         2014   HCC                 China     Asian       PB               TaqMan            68     102       40    210    171     160   79    410    0.39   0.000   12
  Hua \[[@R66]\]         2014   Gastric cancer      China     Asian       HB               Mass ARRAY        92     182       127   401    120     230   83    433    0.46   0.144   9
  Oltulu \[[@R65]\]      2014   Lung cancer         Turkey    Caucasian   HB               PCR-RFLP          35     44        16    95     46      47    6     99     0.30   0.194   7
  Wang \[[@R64]\]        2014   Breast cancer       China     Asian       HB               PCR-RFLP          93     210       171   474    162     216   123   501    0.46   0.003   9
  Zhang \[[@R63]\]       2014   HCC                 China     Asian       PB               PCR               205    312       107   624    542     790   274   1606   0.42   0.631   10
  Chen \[[@R62]\]        2015   Ovarian cancer      China     Asian       HB               Mass ARRAY        120    195       95    410    85      235   122   442    0.54   0.136   9
  Cui \[[@R61]\]         2015   Prostate cancer     China     Asian       HB               PCR-RFLP          198    246       99    543    212     355   186   753    0.48   0.125   10
  Han \[[@R60]\]         2015   Prostate cancer     China     Asian       PB               PCR-RFLP          63     339       534   936    38      331   567   936    0.78   0.230   12
  Kopp \[[@R59]\]        2015   Colorectal cancer   Denmark   Caucasian   PB               KASP              320    449       146   915    679     787   253   1719   0.38   0.311   11
  Li \[[@R58]\]          2015   Osteosarcoma        China     Asian       HB               PCR-RFLP          60     114       46    220    50      106   66    222    0.54   0.551   9
  Liu \[[@R57]\]         2015   NPC                 China     Asian       HB               TaqMan            236    331       117   684    274     438   195   907    0.46   0.420   9
  Liu \[[@R57]\]         2015   NPC                 China     Asian       HB               TaqMan            316    438       152   906    336     512   224   1072   0.45   0.262   9
  Pallavi \[[@R56]\]     2015   Cervical cancer     Iran      Asian       HB               PCR-RFLP          98     116       26    240    73      104   113   290    0.57   0.000   9
  Wang \[[@R55]\]        2015   Lung cancer         China     Asian       HB               PCR-RFLP          113    219       89    421    89      205   131   425    0.55   0.595   10
  Wang \[[@R54]\]        2015   Thyroid carcinoma   China     Asian       HB               PCR-PAGE          106    186       60    352    171     209   79    459    0.40   0.273   11
  Zhang \[[@R53]\]       2015   Lung cancer         China     Asian       HB               PCR-RFLP          434    252       32    718    352     290   76    718    0.31   0.162   9
  Eskandari \[[@R52]\]   2016   Breast cancer       Iran      Asian       HB               AS-PCR            96     122       18    236    62      106   35    203    0.43   0.368   8
  Lu \[[@R51]\]          2016   Ovarian cancer      China     Asian       HB               PCR-RFLP          115    351       221   687    95      339   253   687    0.61   0.271   10
  Rybka \[[@R50]\]       2016   AML                 Poland    Caucasian   HB               PCR               25     30        7     62     43      69    14    126    0.38   0.079   4

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OSCC, oral squamous cell carcinoma; CLL, chronic lymphocytic leukemia; RCC, renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; ESCC, esophageal squamous cell carcinoma; EC, endometrial carcinoma; AML, acute myeloid leukemia; PB, population based; HB, hospital based; PCR-PAGE, polymerase chain reaction-polyacrylamide gel electrophoresis; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-CE, polymerase chain reaction-capillary electrophoresis; PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism; KASP, kompetitive allele specific PCR; AS-PCR, allele-specific polymerase chain reaction.

Meta-analysis results {#s2_2}
---------------------

The main results of this meta-analysis are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Overall, the pooled analysis demonstrated a significant, negative association between the *NFKB1* -94ins/delATTG polymorphism and overall cancer risk under all five genetic models (described in the Materials and Methods section): DD vs. II: OR = 0.75, 95% CI = 0.64-0.87; ID vs. II: OR = 0.91, 95% CI = 0.83-0.99; DD vs. ID/II: OR = 0.81, 95% CI = 0.71-0.91; ID/DD vs. II: OR = 0.86, 95% CI = 0.78-0.95; and D vs. I: OR = 0.88, 95% CI = 0.81-0.95.

###### Meta-analysis of the association between the *NFKB1* -94ins/delATTG (rs28362491) polymorphism and overall cancer risk

  Variables           No. of studies   Sample size    Homozygous             Heterozygous   Recessive              Dominant   Allele                                                                                   
  ------------------- ---------------- -------------- ---------------------- -------------- ---------------------- ---------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  All                 50               18299/ 23484   **0.75 (0.64-0.87)**   \<0.001        **0.91 (0.83-0.99)**   \<0.001    **0.81 (0.71-0.91)**   \<0.001   **0.86 (0.78-0.95)**   \<0.001   **0.88 (0.81-0.95)**   \<0.001
  Cancer type                                                                                                                                                                                                          
  HCC                 6                1471/ 3390     0.65 (0.38-1.11)       \<0.001        0.82 (0.56-1.19)       \<0.001    0.74 (0.54-1.02)       0.006     0.75 (0.50-1.15)       \<0.001   0.80 (0.61-1.07)       \<0.001
  Lung                5                2793/ 2921     0.77 (0.48-1.26)       \<0.001        **0.84 (0.74-0.96)**   0.337      0.82 (0.54-1.26)       \<0.001   0.83 (0.67-1.03)       0.012     0.88 (0.70-1.09)       \<0.001
  Colorectal          4                2399/ 3653     0.96 (0.65-1.43)       0.001          1.08 (0.79-1.47)       \<0.001    0.92 (0.69-1.22)       0.022     1.05 (0.77-1.44)       \<0.001   1.01 (0.82-1.24)       \<0.001
  NPC                 4                2053/ 2482     **0.66 (0.56-0.78)**   0.467          **0.85 (0.75-0.97)**   0.537      **0.73 (0.63-0.85)**   0.755     **0.79 (0.69-0.90)**   0.371     **0.81 (0.74-0.89)**   0.316
  Prostate            4                1930/ 2166     **0.59 (0.48-0.72)**   0.684          **0.74 (0.62-0.88)**   0.803      **0.77 (0.65-0.92)**   0.267     **0.69 (0.59-0.81)**   0.760     **0.79 (0.72-0.87)**   0.540
  Ovarian             4                1463/ 1573     **0.54 (0.40-0.73)**   0.173          **0.73 (0.61-0.87)**   0.416      **0.68 (0.52-0.89)**   0.102     **0.67 (0.56-0.79)**   0.462     **0.75 (0.65-0.86)**   0.181
  Bladder             3                1058/ 1175     0.93 (0.40-2.21)       \<0.001        0.95 (0.74-1.22)       0.193      0.97 (0.43-2.17)       \<0.001   0.96 (0.67-1.37)       0.026     0.97 (0.66-1.43)       \<0.001
  Gastric             3                1062/ 1429     0.97 (0.41-2.31)       \<0.001        0.88 (0.60-1.30)       0.032      1.11 (0.57-2.15)       \<0.001   0.90 (0.54-1.49)       0.002     0.98 (0.65-1.50)       \<0.001
  Cervical            3                573/ 755       0.41 (0.15-1.11)       0.001          0.85 (0.67-1.08)       0.627      0.44 (0.17-1.12)       0.001     0.69 (0.45-1.04)       0.050     0.66 (0.39-1.10)       \<0.001
  OSCC                2                674/ 721       **0.49 (0.33-0.72)**   0.222          **0.67 (0.51-0.88)**   0.570      **0.63 (0.49-0.81)**   0.308     **0.60 (0.46-0.77)**   0.377     **0.70 (0.60-0.82)**   0.300
  Breast              2                710/ 704       0.92 (0.13-6.42)       \<0.001        1.13 (0.51-2.54)       0.002      0.85 (0.20-3.61)       \<0.001   1.13 (0.38-3.37)       \<0.001   1.04 (0.43-2.53)       \<0.001
  Others              10               2113/ 4263     1.07 (0.88-1.31)       0.281          1.16 (0.94-1.42)       0.006      1.00 (0.86-1.16)       0.483     1.14 (0.94-1.38)       0.008     1.06 (0.95-1.19)       0.062
  Ethnicity                                                                                                                                                                                                            
   Asians             38               15079/ 18673   **0.67 (0.55-0.80)**   \<0.001        **0.86 (0.79-0.94)**   \<0.001    **0.75 (0.65-0.86)**   \<0.001   **0.80 (0.72-0.89)**   \<0.001   **0.83 (0.76-0.91)**   \<0.001
   Chinese            34               13834/ 16989   **0.68 (0.56-0.81)**   \<0.001        **0.84 (0.77-0.93)**   \<0.001    **0.77 (0.67-0.88)**   \<0.001   **0.80 (0.71-0.89)**   \<0.001   **0.84 (0.76-0.91)**   \<0.001
   Caucasians         12               3220/ 6559     1.08 (0.92-1.27)       0.221          1.11 (0.94-1.30)       0.004      1.02 (0.88-1.17)       0.269     1.10 (0.95-1.28)       0.010     1.06 (0.98-1.15)       0.141
  Source of control                                                                                                                                                                                                    
   HB                 40               12614/ 15682   **0.70 (0.58-0.85)**   \<0.001        **0.88 (0.80-0.98)**   \<0.001    **0.76 (0.65-0.89)**   \<0.001   **0.84 (0.74-0.94)**   \<0.001   **0.85 (0.77-0.94)**   \<0.001
  PB                  10               5685/ 9550     0.95 (0.79-1.15)       0.001          1.00 (0.86-1.15)       0.002      0.98 (0.88-1.09)       0.161     0.98 (0.84-1.14)       \<0.001   0.98 (0.90-1.08)       \<0.001
  Quality score                                                                                                                                                                                                        
  \>9                 19               9894/ 13117    0.87 (0.73-1.04)       \<0.001        0.93 (0.84-1.04)       \<0.001    0.92 (0.80-1.05)       \<0.001   0.91 (0.81-1.03)       \<0.001   0.94 (0.86-1.02)       \<0.001
  ≤9                  31               8405/ 12115    **0.68 (0.53-0.86)**   \<0.001        0.89 (0.79-1.01)       \<0.001    **0.73 (0.60-0.88)**   \<0.001   **0.83 (0.71-0.96)**   \<0.001   **0.84 (0.75-0.95)**   \<0.001

Het, heterogeneity; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; OSCC, oral squamous cell carcinoma; HB, hospital-based; PB, population-based.

![Forest plot of the association between the *NFKB1* -94ins/delATTG polymorphism and overall cancer susceptibility in the allele contrast model\
The horizontal lines represent the study-specific ORs and 95% CIs, respectively. The diamond represents the pooled OR and corresponding 95% CI.](oncotarget-08-9806-g002){#F2}

Stratified analysis by cancer type revealed that the -94ins/delATTG polymorphism significantly decreased lung cancer risk (ID vs. II: OR = 0.84, 95% CI = 0.74-0.96), nasopharyngeal carcinoma risk (DD vs. II: OR = 0.66, 95% CI = 0.56-0.78; ID vs. II: OR = 0.85, 95% CI = 0.75-0.97; DD vs. ID/II: OR = 0.73, 95% CI = 0.63-0.85; ID/DD vs. II: OR = 0.79, 95% CI = 0.69-0.90; D vs. I: OR = 0.81, 95% CI = 0.74-0.89), prostate cancer risk (DD vs. II: OR = 0.59, 95% CI = 0.48-0.72; ID vs. II: OR = 0.74, 95% CI = 0.62-0.88; DD vs. ID/II: OR = 0.77, 95% CI = 0.65-0.92; ID/DD vs. II: OR = 0.69, 95% CI = 0.59-0.81; D vs. I: OR = 0.79, 95% CI = 0.72-0.87), ovarian cancer risk (DD vs. II: OR = 0.54, 95% CI = 0.40-0.73; ID vs. II: OR = 0.73, 95% CI = 0.61-0.87; DD vs. ID/II: OR = 0.68, 95% CI = 0.52-0.89; ID/DD vs. II: OR = 0.67, 95% CI = 0.56-0.79; D vs. I: OR = 0.75, 95% CI = 0.65-0.86), and oral squamous cell carcinoma risk (DD vs. II: OR = 0.49, 95% CI = 0.33-0.72; ID vs. II: OR = 0.67, 95% CI = 0.51-0.88; DD vs. ID/II: OR = 0.63, 95% CI = 0.49-0.81; ID/DD vs. II: OR = 0.60, 95% CI = 0.46-0.77; D vs. I: OR = 0.70, 95% CI = 0.60-0.82). However, no correlation was observed between *NFKB1* -94ins/delATTG polymorphism and other types of cancer.

When stratified by population, a significant association between *NFKB1* -94ins/delATTG polymorphism and decreased cancer risk among Asians was detected under all genetic models (DD vs. II: OR = 0.67, 95% CI = 0.55-0.80; ID vs. II: OR = 0.86, 95% CI = 0.79-0.94; DD vs. ID/II: OR = 0.75, 95% CI = 0.65-0.86; ID/DD vs. II: OR = 0.80, 95% CI = 0.72-0.89; D vs. I: OR = 0.83, 95% CI = 0.76-0.91). As most of the studies were performed on the Chinese population, we determined the association of *NFKB1* -94ins/delATTG polymorphism with cancer risk on Chinese subjects. In this case, the results also showed a protective role against cancer (DD vs. II: OR = 0.68, 95% CI = 0.56-0.81; ID vs. II: OR = 0.84, 95% CI = 0.77-0.93; DD vs. ID/II: OR = 0.77, 95% CI = 0.67-0.88; ID/DD vs. II: OR = 0.80, 95% CI = 0.71-0.89; D vs. I: OR = 0.84, 95% CI = 0.76-0.91). No association was observed, however, for Caucasians.

Upon stratification based on the sources of controls, the *NFKB1* -94ins/delATTG polymorphism had a protective role against cancer in hospital-based groups (DD vs. II: OR = 0.70, 95% CI = 0.58-0.85; ID vs. II: OR = 0.88, 95% CI = 0.80-0.98; DD vs. ID/II: OR = 0.76, 95% CI = 0.65-0.89; ID/DD vs. II: OR = 0.84, 95% CI = 0.74-0.94; D vs. I: OR = 0.85, 95% CI = 0.77-0.94).

After stratification by quality score, a significantly decreased cancer risk was observed for studies with quality scores ≤9 (DD vs. II: OR = 0.68, 95% CI = 0.53-0.86; DD vs. ID/II: OR = 0.73, 95% CI = 0.60-0.88; ID/DD vs. II: OR = 0.83, 95% CI = 0.71-0.96; D vs. I: OR = 0.84, 95% CI = 0.75-0.95).

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

Statistically significant between-study heterogeneity was found in the pooled analysis under the five genetic models (*P* \< 0.001). Thus, the random-effect model was applied to calculate the ORs and 95% CIs. Sensitivity analysis using the leave-one-out cross-validation method was conducted to assess the impact of each single study on the overall risk estimates. The omission of each individual study did not have substantial influence on the risk estimates, supporting the credibility and reliability of this meta-analysis (data not shown).

Publication bias {#s2_4}
----------------

Publication bias was assessed by Begg\'s funnel plot and quantitative Egger\'s test. The funnel plot showed a symmetrical shape (Figure [3](#F3){ref-type="fig"}), suggesting no publication bias, a conclusion further supported by the Egger\'s test (DD vs. II: *P* = 0.158; ID vs. II: *P* = 0.340, DD vs. ID/II: *P* = 0.157; ID/DD vs. II: *P* = 0.221; and D vs. I: *P* = 0.250).

![Funnel plot analysis to detect publication bias for *NFKB1* -94ins/delATTG polymorphism under the allele contrast model\
Each point represents a separate study.](oncotarget-08-9806-g003){#F3}

Trial sequential analysis and false-positive report probability (FPRP) analyses {#s2_5}
-------------------------------------------------------------------------------

To minimize random errors and strengthen the robustness of our conclusions, we performed TSA (Figure [4](#F4){ref-type="fig"}). This analysis showed that the cumulative z-curve crossed the trial sequential monitoring boundary before reaching the required information size, suggesting that the cumulative evidence is sufficient and no further evidence is needed to verify the conclusions.

![Trial sequential analysis for *NFKB1* -94ins/delATTG polymorphism under the allele contrast model](oncotarget-08-9806-g004){#F4}

We finally calculated the FPRP values for all observed significant findings. With the assumption of a prior probability of 0.1, the FPRP values were all \<0.20, suggesting that these significant associations were noteworthy (Table [3](#T3){ref-type="table"}).

###### False-positive report probability values for associations between the *NFKB1* -94ins/delATTG polymorphism and overall cancer risk

  Variables                  OR (95% CI)        *P* ^a^        Power ^b^   Prior Probability                           
  -------------------------- ------------------ -------------- ----------- ------------------- ------- ------- ------- -------
  Homozygous (DD vs. II)                                                                                               
   All                       0.75 (0.64-0.87)   2.45\*10^-4^   1.000       0.001               0.002   0.024   0.197   0.710
   NPC                       0.66 (0.56-0.78)   1.99\*10^-6^   0.652       0.000               0.000   0.000   0.003   0.030
   Prostate                  0.59 (0.48-0.72)   6.40\*10^-7^   0.860       0.000               0.000   0.000   0.001   0.007
   Ovarian                   0.54 (0.40-0.73)   6.62\*10^-6^   0.612       0.000               0.000   0.001   0.011   0.098
   OSCC                      0.49 (0.33-0.72)   3.26\*10^-4^   0.388       0.003               0.008   0.077   0.457   0.894
   Asians                    0.67 (0.55-0.80)   1.81\*10^-5^   1.000       0.000               0.000   0.002   0.018   0.153
   Chinese                   0.68 (0.56-0.81)   3.45\*10^-5^   1.000       0.000               0.000   0.003   0.033   0.257
   HB                        0.70 (0.58-0.85)   3.30\*10^-4^   1.000       0.001               0.003   0.032   0.248   0.767
   QS ≤9                     0.68 (0.53-0.86)   1.63\*10^-3^   1.000       0.005               0.014   0.139   0.620   0.942
  Heterozygous (ID vs. II)                                                                                             
   All                       0.91 (0.83-0.99)   0.024          1.000       0.066               0.175   0.700   0.959   0.996
   Lung                      0.84 (0.74-0.96)   7.74\*10^-3^   1.000       0.023               0.065   0.434   0.885   0.987
   NPC                       0.85 (0.75-0.97)   0.017          1.000       0.048               0.131   0.623   0.943   0.994
   Prostate                  0.74 (0.62-0.88)   7.44\*10^-4^   0.998       0.002               0.007   0.069   0.427   0.882
   Ovarian                   0.73 (0.61-0.87)   5.68\*10^-4^   0.979       0.002               0.005   0.054   0.367   0.853
   OSCC                      0.67 (0.51-0.88)   3.99\*10^-3^   0.800       0.015               0.043   0.331   0.833   0.980
   Asians                    0.86 (0.79-0.94)   7.59\*10^-4^   1.000       0.002               0.007   0.070   0.431   0.884
   Chinese                   0.84 (0.77-0.93)   4.59\*10^-4^   1.000       0.001               0.004   0.043   0.314   0.821
   HB                        0.88 (0.80-0.98)   0.015          1.000       0.043               0.118   0.596   0.937   0.993
  Recessive (DD vs. ID/II)                                                                                             
   All                       0.81 (0.71-0.91)   3.22\*10^-4^   1.000       0.001               0.003   0.031   0.243   0.763
   NPC                       0.73 (0.63-0.85)   3.26\*10^-5^   0.841       0.000               0.000   0.004   0.037   0.279
   Prostate                  0.77 (0.65-0.92)   3.78\*10^-3^   0.999       0.011               0.033   0.272   0.791   0.974
   Ovarian                   0.68 (0.52-0.89)   4.62\*10^-3^   0.976       0.014               0.041   0.319   0.826   0.979
   OSCC                      0.63 (0.49-0.81)   2.37\*10^-4^   0.356       0.002               0.006   0.062   0.399   0.869
   Asians                    0.75 (0.65-0.86)   6.02\*10^-5^   1.000       0.000               0.001   0.006   0.057   0.376
   Chinese                   0.77 (0.67-0.88)   1.44\*10^-4^   1.000       0.000               0.001   0.014   0.126   0.591
   HB                        0.76 (0.65-0.89)   5.23\*10^-4^   1.000       0.002               0.005   0.049   0.343   0.840
   QS ≤9                     0.73 (0.60-0.88)   1.23\*10^-3^   1.000       0.004               0.011   0.109   0.551   0.925
  Dominant (ID/DD vs. II)                                                                                              
   All                       0.86 (0.78-0.95)   2.68\*10^-4^   1.000       0.008               0.024   0.210   0.728   0.964
   NPC                       0.79 (0.69-0.90)   2.94\*10^-4^   0.997       0.001               0.003   0.028   0.227   0.747
   Prostate                  0.69 (0.59-0.81)   8.36\*10^-6^   0.796       0.000               0.000   0.001   0.010   0.095
   Ovarian                   0.67 (0.56-0.79)   3.45\*10^-6^   0.531       0.000               0.000   0.001   0.006   0.061
   OSCC                      0.60 (0.46-0.77)   9.87\*10^-5^   0.186       0.002               0.005   0.050   0.347   0.842
   Asians                    0.80 (0.72-0.89)   9.05\*10^-5^   1.000       0.000               0.001   0.009   0.083   0.475
   Chinese                   0.80 (0.71-0.89)   9.39\*10^-5^   1.000       0.000               0.001   0.009   0.086   0.484
   HB                        0.84 (0.74-0.94)   2.29\*10^-3^   1.000       0.007               0.020   0.185   0.696   0.958
   QS ≤9                     0.83 (0.71-0.96)   0.013          1.000       0.038               0.105   0.563   0.929   0.992
  Allele (D vs. I)                                                                                                     
   All                       0.88 (0.81-0.95)   8.86\*10^-4^   1.000       0.003               0.008   0.081   0.469   0.899
   NPC                       0.81 (0.74-0.89)   9.60\*10^-6^   1.000       0.000               0.000   0.001   0.009   0.088
   Prostate                  0.79 (0.72-0.87)   1.03\*10^-6^   1.000       0.000               0.000   0.000   0.001   0.010
   Ovarian                   0.75 (0.65-0.86)   3.47\*10^-5^   1.000       0.000               0.000   0.003   0.033   0.257
   OSCC                      0.70 (0.60-0.82)   1.11\*10^-5^   0.809       0.000               0.000   0.001   0.014   0.121
   Asians                    0.83 (0.76-0.91)   4.78\*10^-5^   1.000       0.000               0.000   0.005   0.046   0.323
   Chinese                   0.84 (0.76-0.91)   9.24\*10^-5^   1.000       0.000               0.001   0.009   0.085   0.480
   HB                        0.85 (0.77-0.94)   9.63\*10^-4^   1.000       0.003               0.009   0.087   0.490   0.906
   QS ≤9                     0.84 (0.75-0.95)   4.84\*10^-3^   1.000       0.014               0.042   0.324   0.829   0.980

CI, confidence interval; OR, odds ratio; NPC, Nasopharyngeal carcinoma; OSCC, oral squamous cell carcinoma; HB, Hospital based; QS, quality score.

^a^ Chi-square test was adopted to calculate the genotype frequency distributions.

^b^ Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

DISCUSSION {#s3}
==========

In this meta-analysis, we found that the *NFKB1* -94ins/delATTG promoter polymorphism was significantly associated with decreased overall cancer risk under the five genetic models. To the best of our knowledge, this is the most comprehensive meta-analysis on this topic by now.

Numerous studies have suggested that polymorphisms in genes encoding inflammatory response factors, such as *TNF-alpha* -308G\>A \[[@R6]\], *IL6* -174G\>C \[[@R90]\], and *NFKBIA* -826C\>T \[[@R91]\] may contribute to cancer susceptibility. Song et al. \[[@R92]\] reported that the *NFKB1* -94ins/delATTG polymorphism analyzed here (rs28362491) increased the risk of colorectal cancer in a Southern Chinese population; this association was also observed in several publications \[[@R71]\]. However, contradictory conclusions were also reported, namely a null association, or decreased cancer susceptibility. To address this controversy, at least six meta-analyses were performed. The first one, performed in 2011 by Zou et al. \[[@R32]\], included only 2,743 cases and 2,195 controls from 11 studies. They did not observe any association between the -94ins/delATTG variant and overall cancer. However, an ethno-specific association was detected by subgroup analysis; the D allele was protective against cancer in Asians, but increased the risk in Caucasians. Afterwards, Wang et al. \[[@R33]\] conducted an updated meta-analysis including 5,196 cases and 6,614 controls from 19 publications. They found that variant homozygotes (DD) had a decreased risk of cancer compared with wild-type homozygotes (II). The association was also found under the dominant genetic model (DD+DI vs. II). In subgroup analysis, a significantly decreased risk was observed in Asians but not in Caucasians. In addition, this susceptibility was cancer-specific, as it was observed for all cancer types examined, except for colorectal cancer. In 2014, four updated meta-analyses were published. Upon revision of 6,494 cases and 9,884 controls from 23 studies, Xu et al. \[[@R29]\] found that the -94ins/delATTG polymorphism was significantly associated with increased cancer risk under all the inheritance models. Stratified analysis by cancer type showed significant associations for ovarian cancer, hepatocellular carcinoma, and oral squamous cell carcinoma, but not for bladder cancer or lung cancer. Ethnicity subgroup analysis indicated that the polymorphism contributed to cancer risk in the Asian, but not the Caucasian, population. Another study by Yang et al. \[[@R28]\], which included 21 reports with 6,127 cases and 9,238 controls, also detected an increased overall cancer risk. Stratified analysis revealed a significant association between the polymorphism and ovarian, oral, and prostate cancers. These findings were also specific to the Asian population. Duan et al. \[[@R31]\] reviewed a total of 25 studies that included 8,750 cancer cases and 9,170 controls. They found that the insertion allele of the -94ins/delATTG polymorphism significantly increased cancer risk, both in overall genetic analysis as well as in Asians. Stratified analysis revealed that the polymorphism was associated with increased risk for oral squamous cell carcinoma and ovarian cancer, but not for colorectal cancer, bladder cancer, or renal cell cancer. In another meta-analysis involving 7,281 cases and 10,039 controls from 25 case-control studies, Nian et al. \[[@R30]\] found that the -94ins/delATTG polymorphism was significantly associated with decreased susceptibility to cancer in overall population under homozygous, recessive, dominant, and allele contrast models. Subgroups analysis based on ethnicity revealed that the polymorphism conferred decreased cancer susceptibility in the Asian population.

Since then, approximately 20 new relevant case-control studies in English and Chinese have emerged, some containing large samples and convincing results. Our study re-evaluated the impact of the *NFKB1* -94ins/delATTG polymorphism on cancer risk. In line with some previous meta-analyses, our pooled analysis revealed a significant association with decreased cancer risk under all five genetic models. Conversely, we found that the del allele of the *NFKB1* -94ins/delATTG polymorphism conferred a significantly decreased risk of cancer in the pooled analysis. Compared with the ins allele, the ins allele significantly enhances the binding ability to nuclear proteins and increases transcriptional activity, which eventually upregulates p50 (the active NF-κB1 subunit) expression \[[@R21]\]. Given the tumor-promoting role of p50 and NF-κB, it is biologically plausible that the -94del allele confers decreased cancer susceptibility.

In line with previous data, our study detected a significant association between the -94ins/delATTG polymorphism and cancer risk in Asians, but not in Caucasians, under all five genetic models. It is thus likely that the allelic distribution of this polymorphism vary geographically and ethnically, thus leading to the discrepancies in cancer risk. This may indicate that these groups have distinct environmental or genetic cancer co-etiologies. Stratification by cancer type showed that the *NFKB1* -94ins/delATTG polymorphism was inversely associated with the risk of lung cancer, nasopharyngeal carcinoma, prostate cancer, ovarian cancer, and oral squamous cell carcinoma, but no association was found for hepatocellular carcinoma, colorectal cancer, bladder cancer, gastric cancer, cervical cancer, breast cancer, or other cancers. This phenomenon may be partly attributed to the inherent heterogeneity of oncogenic progression in different cancer types \[[@R93]\], although the insufficient statistical power caused by the relatively small number of studies on each cancer type may also be a factor.

The credibility of our conclusions is supported by the inclusion of Chinese-language studies, exclusion of publications with controls violating the Hardy-Weinberg equilibrium, and inclusion of subgroup, publication bias, and sensitivity analyses. Among the limitations of our meta-analysis are a significant between-study heterogeneity, detected in some comparisons, which may diminish the strength of our conclusions. The source of this heterogeneity may be ascribed to sample size, genotyping methods, ethnicity, source of controls, as well as the studies' diverse quality scores. Second, we assessed the association between the *NFKB1* -94ins/delATTG polymorphism and cancer risk from a genetic perspective only, by using unadjusted ORs. Multiple potentially influential factors such as life style, environmental exposure, and gene-environment interactions should be considered to obtain a more precise risk estimation. Third, the number of studies in certain subgroup analyses was too small to obtain a reliable association. For instance, only six publications were included for hepatocellular carcinoma, and fewer studies were available for breast cancer and oral squamous cell carcinoma, which restrains further analysis for risk factors. Finally, the meta-analysis is a type of retrospective study with several inherent drawbacks: inconsistent qualities of primary studies, incomplete histological details, misclassified genotypes, different definitions of disease status, and improperly matched sources of controls.

In conclusion, despite these limitations, and in agreement with several previous studies, this meta-analysis draws the robust conclusion that *NFKB1* -94ins/delATTG polymorphism is associated with decreased cancer risk, especially in the Asian population. These findings indicate a possible involvement of *NFKB1* in the etiology of tumorigenesis, and suggest the potentially relevant therapeutic value of NF-κB modulation in cancer prevention. Further multi-center, well-designed investigations with larger sample sizes that include gene-environment interactions assessment are warranted to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We performed a comprehensive literature search by using the PubMed and EMBASE databases, without language limitations, up to July 1, 2016. The following search terms were used: "polymorphism or SNP or single nucleotide polymorphism or variant" and "NFKB1/NF-κB1 or nuclear factor kappa B1", and "tumor or cancer or neoplasm or carcinoma". We also searched the China National Knowledge Infrastructure (CNKI) and WANFANG databases to obtain additional, relevant studies. Retrieved articles were manually screened to determine eligible studies. When two or more publications containing overlapping data were found, the largest study was included in the final meta-analysis.

Inclusion/exclusion criteria {#s4_2}
----------------------------

All articles included in the current analysis met the following criteria: 1) evaluation of the association between *NFKB1* -94ins/delATTG polymorphism and cancer risk; 2) case-control studies; 3) sufficient information provided to estimate ORs and 95% CIs; 4) *NFKB1* -94ins/delATTG genotype frequency in agreement with HWE in controls. Exclusion criteria were as follows: 1) case-only studies; 2) meta-analysis or reviews; 3) studies that lacked detailed genotyping data; 4) duplicates of previous publications.

Data extraction {#s4_3}
---------------

Two authors (Z.Z. and W.F.) evaluated all eligible studies independently and extracted the following information: first author\'s surname, year of publication, cancer type, country, ethnicity, source of controls, genotyping methods, and genetic distribution of cases and controls. Stratification analyses were conducted by cancer type, ethnicity (Asians, Caucasians), source of control (hospital-based and population-based) and quality score (\>9 and ≤9). If a study contained two or more ethnic groups or cancer types, we divided the study accordingly.

Trial sequential analysis {#s4_4}
-------------------------

TSA was performed as described by us previously \[[@R94]\]. Briefly, after adopting a level of significance of 5% for type I error and of 30% for type II error, the required information size was calculated, and TSA monitoring boundaries were built.

FPRP analysis {#s4_5}
-------------

The FPRP values at different prior probability levels for all significant findings were calculated as described by us previously \[[@R95]\]. Briefly, 0.2 was set as FPRP threshold and assigned a prior probability of 0.01 to detect an OR of 0.67 (for protective effects) for an association with genotypes under investigation. A FPRP value \<0.2 denoted a noteworthy association.

Statistical methods {#s4_6}
-------------------

Goodness-of-fit χ^2^ test was used to assess HWE in the control subjects. Departure from HWE was assessed using a *P* \< 0.05 as threshold in each study. The strength of the association between *NFKB1* -94ins/delATTG polymorphism and cancer risk was assessed by calculating ORs and corresponding 95% CIs. Five genetic models were adopted: homozygote model (DD, homozygous deletion (del/del) vs. II, homozygous insertion (ins/ins) or wild-type); heterozygote model (ID, heterozygous ins/del vs. II); recessive model (DD vs. ID/II); dominant model (ID/DD vs. II); and allele contrast model (D vs. I). Subgroup and stratification analyses were also performed to test the association by ethnicity, cancer type, source of control and quality score. We performed χ^2^-based Q-test to assess heterogeneity between study results. The fixed-effects model (Mantel-Haenszel method) was used if the studies were found to be homogeneous (with *P* \> 0.10 for the Q-test). Otherwise, the random-effects model (DerSimonian and Laird method) was adopted to estimate the pooled OR \[[@R96]--[@R99]\]. Quality assessment for each study was performed using the quality assessment criteria described previously ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R98]\]. Sensitivity analysis was carried out by individually removing each study and reanalyzing the pooled risk estimates. Potential publication bias was estimated by Begg\'s funnel plot and Egger\'s linear regression, where an asymmetric plot and a *P* value \< 0.05, respectively, indicate the presence of publication bias. All the data management and statistical analyses were completed using STATA software (Stata Corporation, College Station, TX; version 11.0). All the *P* values were two-sided. A *P* value of \< 0.05 was considered statistically significant.
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